Flulaval® Influenza Virus Vaccine, Suspension for Intramuscular Injection, 2008-2009 Formula

Catalog No. NR-17422

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer and Distributor:

ID Biomedical Corporation of Quebec and GlaxoSmithKline

Product Description:

NR-17422 is a trivalent, split-virion, inactivated influenza virus vaccine that contains the hemagglutinin and neuraminidase surface antigens from an influenza A/Brisbane/59/07 (H1N1)-like virus (A/Brisbane/59/07 IVR-148), an A/Brisbane/10/07 (H3N2)-like virus (A/Uruguay/716/07 NYMC X-175C) and the B/Florida/4/06 virus that were predicted to circulate in the United States during the 2008 to 2009 influenza season.[1]

NR-17422 was prepared from virus propagated in the allantoic cavity of embryonated hens' eggs. Each of the influenza virus strains was produced and purified separately. The virus was inactivated with ultraviolet light treatment followed by formaldehyde treatment and then purified by centrifugation and disrupted with sodium deoxycholate. Thimerosal, a mercury derivative, was added as a preservative. Each 0.5 mL dose (10 doses per vial) contains 25 µg of mercury and may also contain residual amounts of eggs proteins, formaldehyde and sodium deoxycholate. Antibiotics were not used in the manufacture of this vaccine.

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL dose contains the recommended ratio of 15 µg each of the hemagglutinin antigens from influenza viruses A/Brisbane/59/07 IVR-148 (H1N1), A/Uruguay/716/07 NYMC X-175C (H3N2) and B/Florida/4/06.

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2008-2009 season are now past their expiration dates.

Material Provided:

Each vial contains 5 mL (10 doses) of purified surface antigen vaccine in phosphate-buffered saline containing 25 µg of mercury.

Packaging/Storage:

NR-17422 is packaged in a 5 mL multi-dose vial. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Flulaval® Influenza Virus Vaccine, Suspension for Intramuscular Injection, 2008-2009 Formula, NR-17422."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Fiore, A. E., et al. "Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008." MMWR Recomm. Rep. 57 (2008): 1-60. PubMed: 18685555.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898